Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy
· seekingalpha.com
Ironwood Pharmaceuticals' Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029. See why IRWD stock is a Buy now.
Ironwood Pharmaceuticals ( IRWD ) is up 126% over the past year, but the bulls still say it has more room to run. On October 2nd it was at $3.64 with a market c...